Genzyme has announced that it will construct an additional manufacturing plant to support the growth of its Myozyme and Lumizume treatments for Pompe disease.

The company held a ceremony in Geel, Belgium, to celebrate the start of construction of the plant, which will cost €250m and will have an 8,000l production capacity and complete purification installation.

The plant marks a growing expansion operation for Genzyme, as production capacity at its adjacent plant has already been increased to 12,000l with the addition of a third bioreactor, scheduled for approval by the end of 2011.

The company aims to increase its complete biologics manufacturing capacity fourfold, and increase the number of markets Myozyme is available in from 48 to 60.